J. Goldman & CO LP Tcr2 Therapeutics Inc. Call Options Transaction History

J. Goldman & CO LP

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2020 Nov 16, 2020	SELL	$13.1 - $20.69 $534,480 - $844,152	-40,800 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $265,608 - $687,480	40,800 New	40,800 $627,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.